At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
pazopanib hydrochloride +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
In Brief
A Phase 2 clinical trial evaluating pazopanib hydrochloride, laboratory biomarker analysis, and 3 other interventions for Adult Angiosarcoma and 3 related conditions. Completed, enrolled 29 participants across 5 sites.
Detailed Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionJan 2019
Study CompletionJan 2021
TodayJul 2026
First PostedOct 31, 2011
Enrollment StartNov 3, 2011
Primary CompletionJan 2, 2019
Study CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 14.7 years ago
Interventions
pazopanib hydrochloridedrug
Given PO
laboratory biomarker analysisother
Correlative studies
positron emission tomographyprocedure
Correlative studies
computed tomographyprocedure
Correlative studies
fludeoxyglucose F 18radiation
Correlative studies